Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Navigating Ryan Specialty Holdings – A Comprehensive Overview

Ryan Specialty shares fell by -2.8% during the day's afternoon session, and are now trading at a price of $61.0. Is it time to buy the dip? To better answer that question, it's essential to check if the market is valuing the company's shares fairly in terms of its earnings and equity levels.

Ryan Specialty's Valuation Is in Line With Its Sector Averages:

Ryan Specialty Holdings, Inc. operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, Europe, and Singapore. The company belongs to the Finance sector, which has an average price to earnings (P/E) ratio of 20.04 and an average price to book (P/B) ratio of 1.86. In contrast, Ryan Specialty has a trailing 12 month P/E ratio of 79.2 and a P/B ratio of 12.06.

Ryan Specialty has moved 47.7% over the last year compared to 24.7% for the S&P 500 — a difference of 23.0%. Ryan Specialty has a 52 week high of $75.97 and a 52 week low of $41.65.

Strong Revenue Growth but Significant Leverage Levels:

2019 2020 2021 2022 2023
Revenue (M) $765 $1,018 $1,433 $1,725 $2,078
Interest Income (M) $36 $47 $79 $105 $120
Operating Margins 13% 16% 13% 17% 17%
Net Margins 8% 7% 5% 4% 3%
Net Income (M) $64 $68 $66 $61 $61
Depreciation & Amort. (M) $5 $4 $5 $6 $9
Free Cash Flow (M) $142 $131 $264 $320 $447
CAPEX (M) $8 $2 $10 $15 $30
Total Debt (M) n/a $1,605 $1,614 $2,007 $2,006
Net Debt / EBITDA nan 4.36 6.41 3.44 3.17
Current Ratio nan 1.0 1.03 1.24 1.16

Ryan Specialty has rapidly growing revenues and increasing reinvestment in the business, generally positive cash flows, and decent operating margins with a stable trend. Furthermore, Ryan Specialty has just enough current assets to cover current liabilities, as shown by its current ratio of 1.16 and significant leverage levels.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS